Chiron's Rabies Vaccine OKed In USA

6 November 1997

Chiron Corp and Behring have revealed that their joint-venture humanrabies vaccine, RabAvert, has been approved by the US Food and Drug Administration for use in pre-exposure vaccination and as a prophylaxis after exposure to rabies. This is the first new rabies vaccine to receive marketing clearance in the USA in almost 10 years, according to the company.

Chiron says that 16 million doses of RabAvert have already been administered in 29 countries since 1985 for both post-exposure prophylaxis and pre-exposure vaccination. None of the patients who were given the vaccine following exposure to rabies have gone on to develop the disease, it adds.

Furthermore, in clinical trials, no cases of rabies were seen in 203 patients followed up for 10 months. Side effects were usually localized and easily controlled, and included pain and swelling of the injection site.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight